Kathleen Lamborn PhD
Adjunct Professor Emeritus of Neurological Surgery
Principal Investigator, Brain Tumor Research Center
Dr. Lamborn, a biostatistician, works with Brain Tumor Research Center (BTRC) investigators and trainees in the design and analysis of BTRC research studies. In particular, together with Dr. Mei Polley, she provides statistical guidance for all clinical trials planned with the BTRC, but also for retrospective reviews based on the BTRC's clinical database, studies using animal models, and in vitro research. Trainees in Neurological Surgery receive biostatistical assistance and training through all of these mechanisms.
Biostatistics and research design
Dr. Lamborn, a co-investigator on many funded BTRC research projects, provides biostatistical input into the design, analysis, and reporting of these studies. Laboratory projects include research using in vitro and animal models. Clinical projects include evaluation of predictive/prognostic factors, including tumor markers, as well as clinical trials. She has also served as Co-Director of the BTRC Tissue Bank, served a 6-year term as Director of the UCSF Cancer Center Biostatistics Core and continues to actively participate in Biostatistics Core activities.
Dr. Lamborn's primary research interest is to utilize statistical methodology to improve the design of experiments and to improve and adapt statistical techniques for use in data analysis and presentation. This research is targeted to address the needs of the specific research projects ongoing within the BTRC, both preclinical and clinical. The goal is efficient trials directly addressing the primary scientific questions in a way that is economical in terms of sample size and time required to complete all components of the study. In addition to the general statistical research effort described above, a substantial effort is ongoing to do research on prognostic factors using the data from the large database containing information on patients treated on clinical trials within the BTRC. Knowledge of prognostic factors will allow improvement of prospective clinical trial study design as well as increasing our ability to interpret results at the time of analysis.
Education, Training, and Previous Positions
- 1966: BA, Mathematics, Oberlin College
1968: MS, Statistics, Stanford University
1970: PhD, Statistics, Stanford University
1970-1974: Assistant Professor of Community Medicine and Mathematics, University of Vermont
1972-1974: Director of Biometry Facility and Biostatistics Masters Degree Program, University of Vermont
1974-1988: Upjohn Company
1988-1993: Northern California Cancer Center, Assistant Director, Biostatistical Consulting Shared Resource
1996-2002: Director, Cancer Center Biostatistics Core, UCSF
1990-present: Quintiles Pacific, currently Senior Scientific Consultant
Selected Professional Memberships and Appointments
- American Statistical Association
Biometric Society
Society for Clinical Trials
American Society of Clinical Oncology
American Association for Cancer Research
Society for Neuro-Oncology
Selected Honors and Awards
- Fellow, American Statistical Association
Magna Cum Laude, Oberlin College
Sigma Xi
Phi Beta Kappa
Woodrow Wilson Fellow
Selected Recent Publications
Lamborn KR, Yung WKA, Chang SM, Wen PY, Coughesy TF, DeAngelis LM, Robins HI, Lieberman F, Fine H, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn J, Aldape K, Hibberts J, Peterson P, Prados MD: Progression-free survival: an important endpoint in evaluating therapy for recurrent high-grade gliomas. Neuro-oncol 2008; 10: 162-70.
Chang EF, Potts MB, Keles GE, , Lamborn KR, Chang SM, Barbaro NM, Berger MS: Seizure characteristics and control following surgical resection in 332 patients with low-grade gliomas. J Neurosurg 2008;108: 227-35.
Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH 2nd, Deen DF: New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor, GRN163. Neuro-oncol 2008;10: 112-20.
Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS: Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008; 26: 1338-45.
Rola R, Fishman K, Baure J, Rosi S, Lamborn KR, Obenaus A, Nelson GA, Fike JR: Hippocampal neurogenesis and neuroinflammation after cranial irradiation with (56)fe particles. Radiat Res 2008;169: 626-32.
Khayal IS, Crawford FW, Saraswathy S, Lamborn KR, Chang SM, Cha S, McKnight TR, Nelson SJ: Relationship between choline and apparent diffusion coefficient in patients with gliomas. J Magn Reson Imaging 2008;27: 718-25.
Chang SM, Lamborn KR, Kuhn JG, Yung WKA, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD: Neuro-oncology clinical trial design for targeted therapies – lessons learned from the North American Brain Tumor Consortium. Neuro-oncol 2008;10: 631-42.
Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, Berger MS. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008;108(2):227-35.
Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, Deangelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD; for the North American Brain Tumor Consortium and the National Cancer Institute. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 2007;13(24):7401-6.
Cha S, Lupo JM, Chen MH, Lamborn KR, McDermott MW, Berger MS, Nelson SJ, Dillon WP. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007;28(6):1078-84.
Entin-Meer M, Yang X, VandenBerg SR, Lamborn KR, Nudelman A, Rephaeli A, Haas-Kogan DA. In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro Oncol 2007;9(2):82-8.
Koo MS, Ozawa T, Santos RA, Lamborn KR, Bollen AW, Deen DF, Kahl SB. Synthesis and comparative toxicology of a series of polyhedral borane anion-substituted tetraphenyl porphyrins. J Med Chem 2007;50(4):820-7.
Yoo H, Baia GS, Smith JS, McDermott MW, Bollen AW, Vandenberg SR, Lamborn KR, Lal A. Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. Clin Cancer Res 2007;13(1):68-75.
Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007;81(3):271-7.
Ozawa T, Faddegon BA, Hu LJ, Bollen AW, Lamborn KR, Deen DF. Response of intracerebral human glioblastoma xenografts to multifraction radiation exposures. Int J Radiat Oncol Biol Phys 2006;66(1):263-70.
Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006;24(22):3651-6.
Keles GE, Chang EF, Lamborn KR, Tihan T, Chang CJ, Chang SM, Berger MS. Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg 2006;105(1):34-40.
Mishra KK, Puri DR, Missett BT, Lamborn KR, Prados MD, Berger MS, Banerjee A, Gupta N, Wara WM, Haas-Kogan DA. The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas. Neuro Oncol 2006;8(2):166-74.
Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J; North American Brain Tumor Consortium. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 2006;8(2):189-93.
Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S. Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum Pathol 2006;37(3):272-82.
Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, McMillan A, Kelsey KT, Aldape K, Lamborn KR, Parsa AT, Sison JD, Prados MD. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 2006;66(8):4531-41.
Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, Xie D, Kelley SK. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 2006;8(1):67-78.
Wrensch M, Rice T, Miike R, McMillan A, Lamborn KR, Aldape K, Prados MD. Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro Oncol 2006;8(1):12-26.
Misra A, Pellarin M, Hu L, Kunwar S, Perhouse M, Lamborn KR, Deen DF, Feuerstein BG. Chromosome transfer experiments link regions on chromosome 7 to radiation resistance in human glioblastoma multiforme. Genes Chromosomes Cancer 2006;45(1):20-30.